
NCI Director's Update

Norman E. Sharpless, M.D.

March 6, 2019




Clinical Trials and Translational Research Advisory Committee Leadership Change



Nancy Davidson, M.D.





New Chair: Patrick J. Loehrer, M.D





FY 2018 RPG FUNDING

Largest increase since FY 2003

FY 2018 ESIs



NCI exceeded
its goal of funding
25% more EarlyStage Investigators

FY 2018 NEW RPGs



Total number of awards up from FY 2017

FY19 Realities: Increasing Costs

- Rent and utilities
- Mandatory assessments and transfers
- NRSA stipend increases
- Increasing award sizes
- Non-competing commitments to RPGs



Upcoming Appropriations Hearings



- FY20 President's Budget Request
- Release expected in March
 - o 3/11 (overview)
 - o 3/18 (detailed)
- Appropriations hearings to follow





Frederick National Laboratory for Cancer Research

CTAC Ad Hoc Working groups

Glioblastoma

Co-Chairs:

Walter J. Curran, Jr. M.D., F.A.C.R.

Chi V. Dang, M.D., Ph.D.

Radiation Oncology

Co-Chairs:

Adam Dicker, M.D., Ph.D., F.A.S.T.R.O. Silvia Formenti, M.D.



www.cancer.gov www.cancer.gov/espanol